Oncology Today with Dr Neil Love
Dr. Neil Love
Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.
Episodes
Mentioned books
Dec 12, 2025 • 1h 43min
Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.CME information and select publications here.
Dec 11, 2025 • 59min
CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma. CME information and select publications here.
Dec 9, 2025 • 1h 5min
HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach
Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer. CME information and select publications here.
Dec 8, 2025 • 1h 28min
Breast Cancer — Highlights from the 2025 ESMO Annual Meeting
Prof Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss the implications of clinical findings in breast cancer recently presented at the 2025 ESMO Annual Meeting. CME information and select publications here.
Dec 5, 2025 • 15min
Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.
Dec 3, 2025 • 52min
Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning
Dr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy. CME information and select publications here.
Dec 2, 2025 • 17min
Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.
7 snips
Nov 29, 2025 • 59min
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Dr. Rinath M Jeselsohn, a specialist in endocrine therapy resistance at Dana-Farber, and Dr. Joyce O’Shaughnessy, known for her expertise in breast cancer trials, dive into the latest in metastatic breast cancer treatments. They discuss the efficacy of oral selective estrogen receptor degraders, the importance of ctDNA testing for ESR1 mutations, and choices for therapy post-CDK4/6 progression. Insights into combination therapies and recent trial results illuminate the complexities of treatment strategies, providing a comprehensive overview for clinicians.
Nov 26, 2025 • 13min
Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dr. Priyanka Sharma, a medical oncologist from The University of Kansas Cancer Center, delves into the latest breast cancer treatment innovations. She highlights promising results from the Destiny Breast 05 study, showcasing a significant reduction in disease events with TDXD. Discussions include the safety concerns of pneumonitis, the impact of new therapies on brain metastasis, and insights from ongoing trials like COMPASS HER2-RD. Sharma emphasizes the importance of quality-of-life considerations and future maintenance strategies for patients.
Nov 21, 2025 • 58min
HER2-Positive Gastrointestinal Cancers — Clinical Investigator Perspectives on Actual Patient Cases
Dr Tanios Bekaii-Saab and Dr Kristen K Ciombor summarize the treatment landscape and review key datasets in consideration of HER2-directed therapies for patients with HER2-positive gastrointestinal cancers. CME information and select publications here.
